T. Rowe Price Associates’s Pfizer PFE Stock Holding History

T. Rowe Price Associates’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$440M	Buy	15,674,905 +3,200,453	+26%	+$85.2M	0.05%	270
2025 Q4	$311M	Buy	12,474,452 +430,918	+4%	+$10.9M	0.03%	348
2025 Q3	$307M	Buy	12,043,534 +791,095	+7%	+$19.5M	0.03%	354
2025 Q2	$273M	Sell	11,252,439 -10,363,057	-48%	-$242M	0.03%	375
2025 Q1	$548M	Buy	21,615,496 +2,743,107	+15%	+$71.8M	0.07%	259
2024 Q4	$501M	Sell	18,872,389 -2,084,603	-10%	-$56.5M	0.06%	269
2024 Q3	$606M	Buy	20,956,992 +3,865,041	+23%	+$113M	0.07%	249
2024 Q2	$478M	Sell	17,091,951 -8,048,018	-32%	-$222M	0.06%	277
2024 Q1	$698M	Sell	25,139,969 -5,404,088	-18%	-$150M	0.09%	211
2023 Q4	$879M	Sell	30,544,057 -18,470,625	-38%	-$558M	0.12%	168
2023 Q3	$1.63B	Buy	49,014,682 +16,418,085	+50%	+$581M	0.24%	90
2023 Q2	$1.2B	Sell	32,596,597 -4,401,435	-12%	-$171M	0.17%	124
2023 Q1	$1.51B	Buy	36,998,032 +1,125,491	+3%	+$48.6M	0.23%	93
2022 Q4	$1.84B	Sell	35,872,541 -595,448	-2%	-$28.5M	0.3%	77
2022 Q3	$1.6B	Buy	36,467,989 +1,529,779	+4%	+$74.3M	0.26%	73
2022 Q2	$1.83B	Sell	34,938,210 -404,839	-1%	-$20.6M	0.23%	92
2022 Q1	$1.83B	Sell	35,343,049 -7,915,667	-18%	-$411M	0.18%	110
2021 Q4	$2.55B	Buy	43,258,716 +4,065,502	+10%	+$201M	0.23%	87
2021 Q3	$1.69B	Buy	39,193,214 +14,898,367	+61%	+$660M	0.16%	129
2021 Q2	$951M	Buy	24,294,847 +1,026,903	+4%	+$39.9M	0.09%	243
2021 Q1	$843M	Sell	23,267,944 -8,284,042	-26%	-$294M	0.08%	248
2020 Q4	$1.16B	Sell	31,551,986 -10,335,226	-25%	-$379M	0.12%	183
2020 Q3	$1.46B	Sell	41,887,212 -8,216,263	-16%	-$288M	0.17%	127
2020 Q2	$1.55B	Sell	50,103,475 -3,505,281	-7%	-$119M	0.2%	106
2020 Q1	$1.66B	Sell	53,608,756 -8,832,207	-14%	-$301M	0.26%	76
2019 Q4	$2.32B	Sell	62,440,963 -226,153	-0.4%	-$8.06M	0.3%	68
2019 Q3	$2.14B	Sell	62,667,116 -35,762,628	-36%	-$1.3B	0.3%	73
2019 Q2	$4.05B	Sell	98,429,744 -14,433,533	-13%	-$573M	0.57%	30
2019 Q1	$4.55B	Sell	112,863,277 -3,296,491	-3%	-$132M	0.67%	25
2018 Q4	$4.81B	Buy	116,159,768 +23,306,717	+25%	+$968M	0.81%	18
2018 Q3	$3.88B	Buy	92,853,051 +14,242,558	+18%	+$548M	0.57%	26
2018 Q2	$2.71B	Buy	78,610,493 +10,130,718	+15%	+$346M	0.41%	48
2018 Q1	$2.31B	Buy	68,479,775 +3,130,433	+5%	+$108M	0.37%	61
2017 Q4	$2.25B	Sell	65,349,342 -157,381	-0.2%	-$5.37M	0.36%	61
2017 Q3	$2.22B	Buy	65,506,723 +2,650,543	+4%	+$85.2M	0.38%	60
2017 Q2	$2B	Sell	62,856,180 -14,390,686	-19%	-$454M	0.36%	62
2017 Q1	$2.51B	Sell	77,246,866 -8,022,937	-9%	-$253M	0.47%	41
2016 Q4	$2.63B	Sell	85,269,803 -13,086,713	-13%	-$400M	0.52%	35
2016 Q3	$3.16B	Sell	98,356,516 -17,039,745	-15%	-$570M	0.64%	26
2016 Q2	$3.85B	Sell	115,396,261 -28,234,812	-20%	-$901M	0.82%	18
2016 Q1	$4.04B	Buy	143,631,073 +25,117,398	+21%	+$717M	0.86%	16
2015 Q4	$3.63B	Buy	118,513,675 +8,172,114	+7%	+$257M	0.76%	20
2015 Q3	$3.29B	Buy	110,341,561 +3,348,271	+3%	+$107M	0.73%	21
2015 Q2	$3.4B	Buy	106,993,290 +14,130,876	+15%	+$461M	0.7%	23
2015 Q1	$3.07B	Buy	92,862,414 +189,665	+0.2%	+$6.03M	0.63%	24
2014 Q4	$2.74B	Buy	92,672,749 +7,746,765	+9%	+$222M	0.58%	28
2014 Q3	$2.38B	Sell	84,925,984 -3,303,723	-4%	-$92.7M	0.52%	42
2014 Q2	$2.48B	Sell	88,229,707 -22,501,805	-20%	-$641M	0.54%	35
2014 Q1	$3.37B	Sell	110,731,512 -1,884,967	-2%	-$56.2M	0.76%	15
2013 Q4	$3.27B	Sell	112,616,479 -9,651,363	-8%	-$281M	0.75%	12
2013 Q3	$3.33B	Buy	122,267,842 +1,656,522	+1%	+$45.1M	0.83%	11
2013 Q2	$3.21B	Buy	+120,611,320	New	+$3.33B	0.86%	9

Other funds holding PFE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

T. Rowe Price Associates's PFE Position: Q1 2026 in Review

T. Rowe Price Associates increased its Pfizer (PFE) stake by 26% in Q1 2026, buying an estimated $85.2M and bringing the position to 15,674,905 shares worth $440M. The position accounts for 0.05% of the portfolio, ranked #270.

T. Rowe Price Associates first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.81B in Q4 2018. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

T. Rowe Price Associates held 15,674,905 shares of Pfizer worth $440M as of Q1 2026.
T. Rowe Price Associates bought 3,200,453 Pfizer shares in Q1 2026, an estimated $85.2M.
Pfizer made up 0.05% of T. Rowe Price Associates's portfolio in Q1 2026, its #270 holding.
T. Rowe Price Associates first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
T. Rowe Price Associates's Pfizer position peaked at $4.81B in Q4 2018.
2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.